Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it is expanding its remote clinical collaboration and virtual training offerings across its portfolio, building on the IIT* (Innovative Imaging Technologies) Reacts collaborative platform. 
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible and have the potential to aid diagnosis and, ultimately, targeted treatment options for patients. 
Treating anxiety and depression with digital mental health therapy has a significant and long-term benefit for recovery, new research amongst NHS service users suggests. The research was undertaken by SilverCloud Health, the world's leading digital mental health company, with the School of Psychology at Trinity College, the University of Dublin, and health economics analysis from the University of Sheffield. 
Siemens Healthineers introduces Ysio X.pree(1), the world's first intelligent X-ray system with integrated AI for optimizing the daily routine of image acquisition in radiography. To assist radiologists with the subsequent image post-processing, Siemens Healthineers also offers its new CE-labeled AI-Rad Companion Chest X-ray, an AI-supported software that aids clinical decision making on upright thorax images. 
Electronic Data Capture (EDC) is no longer sufficient for today’s clinical trials, which are incorporating more virtual components and becoming more decentralized. While traditional EDC systems capture data from forms, patient data in clinical trials is now flowing at a rapid pace and at a high volume from a myriad of novel sources, such as wearables. Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has once again joined forces with the American Telemedicine Association (ATA) to help further the adoption of telehealth across the industry, demonstrating its commitment to connecting care across acute, post-acute and home care settings. 
The U.S. Food and Drug Administration (FDA) permitted marketing of the first game-based digital therapeutic device to improve attention function in children with attention deficit hyperactivity disorder (ADHD). The prescription-only game-based device, called EndeavorRx, is indicated for pediatric patients ages 8 to12 years old with primarily inattentive or combined-type ADHD who have demonstrated an attention issue.